Reaction
Haemophilus Infection reporting signals
As of the last recalculation, Haemophilus Infection appears in 960 FAERS reports alongside 28 co-occurring drug terms. The strongest observed disproportionality signal is CICLESONIDE (PRR 49.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ciclesonide | 30 | 49.3 | 49.4 |
| Mercaptopurine | 33 | 42.7 | 42.8 |
| Fluticasone Furoate | 15 | 27.3 | 27.3 |
| Micafungin Sodium | 9 | 23.2 | 23.2 |
| Mepolizumab | 45 | 20.6 | 20.6 |
| Salmeterol Xinafoate | 8 | 20.3 | 20.3 |
| Valganciclovir Hydrochloride Powder, | 11 | 19.8 | 19.8 |
| Amphotericin B | 11 | 19.2 | 19.3 |
| Palivizumab | 13 | 18.6 | 18.6 |
| Fluticasone Furoate And Vilanterol Trifenatate | 29 | 18.0 | 18.0 |
| Azacitidine For | 14 | 16.9 | 16.9 |
| Itraconazole | 9 | 16.9 | 16.9 |
| Ivacaftor | 6 | 16.5 | 16.5 |
| Remdesivir | 10 | 16.4 | 16.4 |
| Valganciclovir | 13 | 15.1 | 15.2 |
| Valganciclovir Hydrochloride | 13 | 15.1 | 15.2 |
| Cefepime | 9 | 13.7 | 13.7 |
| Daratumumab | 23 | 12.8 | 12.8 |
| Cefepime Hydrochloride | 9 | 12.2 | 12.2 |
| Fludarabine Phosphate | 20 | 11.2 | 11.2 |
| Azacitidine | 14 | 10.4 | 10.4 |
| Canakinumab | 4 | 8.0 | 8.0 |
| Lumacaftor And Ivacaftor | 3 | 7.6 | 7.6 |
| Durvalumab | 7 | 7.5 | 7.5 |
| Dornase Alfa | 6 | 6.7 | 6.7 |
| Obinutuzumab | 5 | 6.6 | 6.6 |
| Axicabtagene Ciloleucel | 3 | 6.6 | 6.6 |
| Ofatumumab | 9 | 5.9 | 5.9 |